IPP Bureau
Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
By IPP Bureau - January 25, 2024
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Lily announces positive gene therapy result for genetic hearing loss
By IPP Bureau - January 25, 2024
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO
By IPP Bureau - January 25, 2024
An accomplished R&D leader and champion of the application of AI to drug discovery
ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
By IPP Bureau - January 24, 2024
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Aster DM Healthcare gets shareholders nod to separate the GCC business
By IPP Bureau - January 24, 2024
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP
By IPP Bureau - January 24, 2024
Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
By IPP Bureau - January 23, 2024
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
By IPP Bureau - January 23, 2024
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
By IPP Bureau - January 23, 2024
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
By IPP Bureau - January 23, 2024
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
By IPP Bureau - January 23, 2024
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
By IPP Bureau - January 23, 2024
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
AstraZeneca Pharma India receives permission to import new drug
By IPP Bureau - January 22, 2024
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
By IPP Bureau - January 22, 2024
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Novo Holdings expands portfolio in cancer diagnostics
By IPP Bureau - January 22, 2024
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
